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ABSTRACT
The persistent rise in global incidence of type 2 diabetes (T2D)
continues to have significant public health and economic implications.
The availability of relevant animal models of T2D is critical to
elucidating the complexity of the pathogenic mechanisms underlying
this disease and the implications this has on susceptibility to T2D
complications. Whilst many high-fat diet-induced rodent models of
obesity and diabetes exist, growing appreciation of the contribution of
high glycaemic index diets on the development of hyperglycaemia
and insulin resistance highlight the requirement for animal models
that more closely represent global dietary patterns reflective of
modern society. To that end, we sought to develop and validate a
murine model of T2D based on consumption of an energy-dense diet
containing moderate levels of fat and a high glycaemic index to better
reflect the aetiopathogenesis of T2D. Male C57BL/6micewere fed an
energy-dense (ED) diet and the development of pathological features
used in the clinical diagnosis of T2D was assessed over a 30-week
period. Compared with control mice, 87% of mice fed an ED diet
developed pathognomonic signs of T2D including glucose
intolerance, hyperglycaemia, glycosylated haemoglobin (HbA1c)
and glycosuria within 30 weeks. Furthermore, dyslipidaemia,
chronic inflammation, alterations in circulating leucocytes and renal
impairment were also evident in ED diet-fedmice comparedwithmice
receiving standard rodent chow. Longitudinal profiling of metabolic
and biochemical parameters provide support of an aetiologically and
clinically relevant model of T2D that will serve as a valuable tool for
mechanistic and therapeutic studies investigating the pathogenic
complications of T2D.
KEY WORDS: Type 2 diabetes, Murine model, Diet-induced,
Glucose intolerance, Insulin resistance
INTRODUCTION
Type 2 diabetes (T2D) continues to be a global health priority
with a significant proportion of health care budgets directed to
management of T2D and its complications. Between 2010 and
2030, the percentage of adults with T2D is expected to increase by
69% in developing countries and 20% in developed countries (Shaw
et al., 2010). T2D is a multifarious, progressive disease involving a
dynamic interplay of lifestyle factors and genetic predisposition that
contribute to changes in glucose metabolism, with overt T2D
typically taking years to develop. The transition from pre-diabetic
states to T2D involves the progressive failure of pancreatic beta (β)-
cells, involving reduced β-cell mass and increased apoptosis.
Persistently elevated blood glucose levels enhance pancreatic β-cell
dysfunction resulting in a more rapid functional deterioration and a
non-compensatory, hyperglycaemic state which is a key diagnostic
feature of T2D (Fonseca, 2009). Vascular complications associated
with T2D arise from a combination of prolonged hyperglycaemia,
advanced glycation end products (AGE) and oxidative stress,
culminating in chronic inflammation and altered cellular function
within many organ systems (Forbes and Cooper, 2013). Patients
with T2D are at increased risk of developing nephropathy,
retinopathy, neuropathy and cardiovascular diseases including
atherosclerosis, myocardial infarction and cerebral ischaemic
accidents (Forbes and Cooper, 2013). Moreover, there is growing
appreciation of the convergence of T2D and communicable diseases
such as tuberculosis, which also account for a significant proportion
of global morbidity and mortality (Bridson et al., 2014; Hodgson
et al., 2015).
Rodent models have contributed significantly to our
understanding of insulin resistance, obesity and diabetes
(King and Bowe, 2015). Genetically altered murine models, such
as Leptdb mice, fail to incorporate the significant nutritional and
polygenic determinants involved in the complex pathogenesis of
clinical T2D. In contrast, diet-induced rodent models of T2D are
considered more akin to the clinical aetiopathology of this disease.
However, there is substantial discordance in the metabolic
phenotypes reported between studies using diet-induced models,
which is confounded by differences in dietary composition and fat
content, age of mice and duration of feeding, along with the rodent
strain and gender (King and Bowe, 2015). Several studies have also
combined a diet-induced rodent model with streptozotocin-induced
destruction of pancreatic β-cells to shorten the length of time
required for development of signs of overt diabetes (Gilbert et al.,
2011; King and Bowe, 2015). The caveat of such models however,
is that the micro- and macro-vascular complications associated with
clinical T2D require significant time to become established and
cannot be achieved in a short-term treatment regime. In addition,
such models have limited utility due to inadvertent toxicity of
streptozotocin on renal and hepatic tissue (Deeds et al., 2011).
The high-fat diet (HFD)-fed C57BL/6model introduced by Surwit
et al. (1988) is used widely as a model of obese T2D; however, a
criticism of this diet is that the fat content (60% of energy) markedly
exceeds typical dietary intake in developed nations (34% of energy)
(Harika et al., 2013). Over the past decade it has become
increasingly apparent that consumption of refined carbohydratesReceived 4 January 2016; Accepted 16 June 2016
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is also an important contributor for the development of metabolic
dysfunction. Energy-dense (ED) diets, characterised by higher
intake of processed and red meat, high-fat foods, sugary desserts
and drinks positively correlate with the incidence of cardiovascular
disease, cancer and T2D (Malik and Hu, 2015; Riccardi et al., 2008;
Rizkalla, 2014). The high glycaemic index associated with ED diets
has the potential to predispose individuals to hyperinsulinaemia,
which is thought to result in pancreatic β-cell exhaustion and
subsequent relative insulin deficiency (Andersson et al., 2010;
Pawlak et al., 2004). Recently, we investigated the impact of an ED
diet (23% and 50.5% total energy from fat and refined carbohydrates,
respectively) on the development of hyperglycaemia and glucose
intolerance in C57BL/6 mice (Hodgson et al., 2013). Progression to
hyperglycaemia and glucose intolerance occurred more rapidly for
mice consuming the ED diet compared with those fed standard (SD)
chow, suggesting that this may be a useful and relevant method for
developing a model of T2D (Hodgson et al., 2013). Therefore, in the
current study we evaluated whether ED feeding over a period of
30 weeks emulates the development of key metabolic and
pathophysiological features associated with progression to overt
T2D. Our findings demonstrate that C57BL/6mice fed an ED diet for
up to 30 weeks develop metabolic and immunological dysfunction
that closely simulates the natural progression of T2D.
RESULTS
ED diet-fed mice develop increased body and adipose tissue
mass
Prior to diet intervention, body mass was comparable between groups
(SD, 19.7±0.4 g vs ED, 19.6±0.4 g; mean±95% confidence interval).
Daily energy intake was significantly higher (1.5-fold) for animals fed
an ED diet (14.7±3.1) compared with SD diet controls (9.9±1.5,
Fig. 1A) and corresponded with significantly increased total body
mass for ED diet-fed mice compared with controls (Fig. 1B) over the
30 week intervention. An overall increase of 28.85% and 60.75% total
bodyweight was observed formice fed SD or EDdiet, respectively, for
30 weeks (Fig. 1B). After 30 weeks of feeding, ED diet mice also
demonstrated greater visceral (∼sixfold, epididymal and
retroperitoneal) and subcutaneous (∼ninefold, inguinal) fat pad mass
when compared with control mice fed SD diet (Table 1).Wet tissue
weights of liver, spleen and pancreas were significantly greater in mice
fed an ED diet for 30 weeks compared with control mice that received
a SD diet (Table 1). There was no significant difference in wet lung
mass for either dietary group after 30 weeks of feeding.
ED diet feeding results in increased fasting blood glucose,
glycosylated haemoglobin (HbA1c) and glucose intolerance
Prior to dietary intervention, fasting blood glucose levels were
comparable between groups (SD, 9.6±1.7 mmol l−1 and ED, 10.8±
3.1 mmol l−1; P=0.10). However, compared with control mice,
fasting blood glucose levels were elevated in ED diet mice by
10 weeks after commencement on the diet and remained significantly
higher throughout the intervention period (Fig. 1C). Despite
comparable levels at baseline, glycated haemoglobin (HbA1c)
concentrations were significantly increased in ED diet-fed mice by
10 weeks (3.3±0.4 vs 2.7±0.2) and remained higher than SD diet
controls throughout the intervention (Fig. 1D). ED diet-fed mice had
significantly impaired glucose tolerancewhen compared with control
mice (Fig. 2). The area under the curve (AUC) derived from the
intraperitoneal glucose tolerance test (GTT) was higher for ED diet-
than SD diet-fed mice at 10, 20 and 30 weeks of the intervention.
These data demonstrate significant metabolic changes within
10 weeks of ED diet feeding with progressive deterioration in the
ability to maintain normoglycaemia and steady increases in
HbA1c, a key diagnostic marker for glycaemic control (American
Diabetes Association, 2014; The Royal Australian College of
General Practitioners and Diabetes Australia, 26 Nov 2015, http://
www.racgp.org.au/your-practice/guidelines/diabetes/3-screening,-risk-
assessment,-case-finding-and-diagnosis/34-diagnosis-of-diabetes),
across the study period.
ED diet-fed mice develop hyperinsulinaemia and insulin
resistance
At the end of the study period (30 weeks), fasting plasma insulin
levels were fivefold higher in ED diet-fed mice compared with
controls (Fig. 3A). Furthermore, insulin secretion in response to
glucose challenge was significantly increased and persistently
higher for mice fed an ED diet compared with SD diet controls
(Fig. S1). The homeostasis model assessment for insulin resistance
(HOMA-IR) was used to determine insulin resistance based on the
fasted insulin and glucose levels after 30 weeks on the diet. ED diet-
fed mice had a 6.8-fold higher HOMA-IR value compared with
control mice (Fig. 3B). Consistent with a hyperinsulinaemic state,
significant differences were also observed in the islet area within
pancreas from SD and ED diet-fed mice (Fig. 3C-E). Compared
with control mice, the percentage of pancreatic islet area was
increased in mice fed an ED diet. Moreover, total insulin content
recovered from pancreas homogenates of ED diet-fed mice was
significantly greater than that of mice fed a SD diet (Fig. 3F).
Combined, these data demonstrate hyperinsulinemia and insulin
resistance in mice fed an ED diet for 30 weeks, together with
pathological changes in the pancreas which are consistent with
compensatory islet hyperplasia described in patients with T2D
(Quan et al., 2013) and other animal models of diabetes (Bock et al.,
2003; Guo et al., 2015).
Haematological and systemic inflammatory changes are
induced in response to ED diet consumption
Haematological data for mice fed a SD or ED diet for 30 weeks was
compared (Table 1). No significant differences were observed in red
blood cell (RBC), white blood cell (WBC) and platelet counts
between mice fed SD or ED diet for 30 weeks using a Coulter®
Ac-T diff haematology analyser. Similarly, haematocrit and total
haemoglobin concentrations were comparable between mice in each
dietary group. Compared with control mice, mean corpuscular
volume (MCV) and mean corpuscular haemoglobin (MCH) were
significantly greater in peripheral blood from ED diet-fed mice. In
contrast, mean corpuscular haemoglobin concentration (MCHC)
was lower in mice fed an ED diet for 30 weeks compared with those
fed a SD diet (Table 1). These data demonstrate that consumption
of an ED diet for 30 weeks contributes to alterations in RBC
morphology and is consistent with changes described in patients
with T2D (Soma and Pretorius, 2015).
Given the pivotal role that leucocytes play in the development
of T2D and its associated complications including increased
susceptibility to infectious diseases (Forbes and Cooper, 2013), we
next investigated whether consumption of an ED diet for 30 weeks
led to changes in key cells of the innate and adaptive immune
response using cell surface marker staining and flow cytometry.
Consistent with the findings using the Coulter® haematology
analyser, peripheral blood total leucocyte yields were comparable
between SD and ED diet-fed mice. No significant differences were
observed in either the absolute number or percentage of
polymorphonuclear cells (PMN), natural killer (NK) and
professional phagocytes in blood from control and ED diet-fed
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mice (Fig. S2). In contrast, the proportion of B-cells was significantly
increased in blood from ED diet-fed mice, corresponding to a trend
for a reduction in the percentage of T cells (Fig. 4A). Further
elucidation of the frequency of particular T cell subsets demonstrated
that the total number of Thelper (Th, CD4
+) cells was reduced in
peripheral blood fromED diet-fedmice. Consequently, the ratio of Th
and Tcytotoxic (Tc, CD8
+) cells was significantly lower for mice fed an
ED diet for 30 weeks, when compared with mice fed a SD diet
(Fig. 4B). Moreover, there were also differences in the proportions of
Tregulatory cells (Treg, CD4
+CD25+) and natural killer T-cells (NKT,
TCRβ+CD1d/α-GalCer dimer+), cells in peripheral blood from SD
and ED diet-fed mice (Fig. 4C,D). Despite absolute numbers of Treg
cells being comparable between dietary groups (P=0.28), the
percentage of Treg cells was significantly lower in blood from mice
fed an ED diet for 30 weeks. Similarly, the percentage of peripheral
blood NKT cells was significantly reduced for ED diet-fed mice with
a trend for an overall reduction in the total number of NKT cells per
ml of blood (P=0.1). In summary, these data demonstrate that by
30 weeks, subclinical systemic inflammation is apparent in mice fed
an ED diet, consistent with the features of clinical T2D (Donath and
Shoelson, 2011; Festa et al., 2006; Khodabandeloo et al., 2015).
Furthermore, contrasting leucocyte profiles were demonstrated
between SD and ED diet-fed mice, particularly within lymphocyte
subsets.
Subclinical chronic inflammation is a hallmark of T2D and is
evidenced by elevation in acute phase proteins such as C-reactive
protein (CRP) and plasminogen activator inhibitor type 1 (PAI-1)
(Festa et al., 2006), and inflammatory cytokines such as tumour
necrosis factor alpha (TNF-α), monocyte chemotactic protein 1
(MCP-1) and interleukin (IL)-6 (Kahn et al., 2014; Khodabandeloo
Fig. 1. Increased caloric intake
corresponds with progressive
weight gain, hyperglycaemia,
formation of advanced glycation
end products, dyslipidemia and
serum inflammatory markers in
mice fed an energy-dense (ED)
diet for 30 weeks. (A) Daily energy
intake and (B) weight gain of mice fed
a standard (SD; n=22) and an ED
(n=23) diet for 30 weeks. Compared
with controls, fasting plasma
(C) glucose concentrations and
(D) glycosylated haemoglobin
(HbA1c) were significantly higher in
ED diet-fed mice throughout the
study period. Mice consuming the ED
diet also had significantly increased
(E) plasma cholesterol and
(F) C-reactive protein (CRP) at 10, 20
and 30 weeks when compared with
control animals. Data are mean±95%
c.i. Significant differences were
analysed by two-way ANOVA and
Sidak’s multiple comparison post
tests and indicated as ***P≤0.001.
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et al., 2015). Therefore, using these markers, we compared plasma
concentrations in mice fed an ED or SD diet for 30 weeks to assess
the development of systemic low-grade inflammation. CRP was
significantly higher in response to the ED diet when compared with
controls at 10, 20 and 30 weeks of the intervention (Fig. 1F,
Table 1). In addition, circulating PAI-1 and MCP-1 levels were
significantly elevated in mice fed an ED diet for 30 weeks,
compared with SD diet-fed control mice (Table 1). A similar trend
was observed for plasma TNF-α levels after 30 weeks of feeding,
though this did not reach statistical significance (Table 1). No
significant differences were observed in plasma concentrations for
IL-6, IL-12p70, interferon gamma (IFN-γ) or IL-10 between SD and
ED diet-fed mice at completion of the study period.
Dyslipidemia and ectopic fat deposition is evident in ED
diet-fed mice
Baseline measurements of fasting total (Fig. 1E), low density
lipoprotein (LDL)- (Fig. S3A) and high density lipoprotein
(HDL)-cholesterol (Fig. S3B) levels in plasma were comparable
for both dietary groups. After 10 weeks on the diet, ED diet-fed
mice demonstrated significantly elevated total cholesterol levels in
comparison with control mice on a SD diet and this trend continued
over the remainder of the 30-week intervention (Fig. 1E).
Similarly, LDL- and HDL-cholesterol levels were 1.2- and 1.7-
fold higher, respectively in ED diet-fed mice by 10 weeks after diet
intervention with these differences persisting to 30 weeks (Fig.
S3A,B). At 10 and 20 weeks post-dietary intervention, circulating
triglycerides were significantly elevated in plasma from ED diet-
fed mice compared with mice fed SD diet (Fig. S3C). However, by
30 weeks plasma triglyceride levels were comparable for SD and
ED diet-fed mice (Table 1, Fig. S3C).
After 30 weeks of feeding, visceral and subcutaneous fat (VAT
and SAT, respectively) pad masses were significantly greater for
mice fed an ED diet when compared with control mice (Table 1).
Furthermore, analysis ofVATmorphology demonstrated an increase
in the mean adipocyte size for ED diet-fed mice compared with
control mice (Fig. 5A,B). In addition to marked visceral and
subcutaneous adiposity, Oil Red O staining of liver revealed
significant hepatic steatosis in mice fed ED diet compared with mice
consuming a SD diet (Fig. 6). Our findings of dyslipidaemia,
extensive ectopic fat deposits in the liver and altered fat topography
are consistent with lipotoxicity described in the pathogenesis of
overt T2D (Cusi, 2010; Kohlgruber and Lynch, 2015).
Effect of ED diet on visceral adipose tissue pathology
Visceral adipose tissue (VAT) plays an important role in obesity
induced insulin resistance through expression of pro-inflammatory
cytokines that propagate the inflammatory response systemically
and promoting insulin resistance and pancreatic β-cell exhaustion
(Cusi, 2010; Kohlgruber and Lynch, 2015). Therefore, having
shown significant differences in the mass of VAT between SD and
ED diet-fed mice, we next compared the inflammatory cytokine
profile of VAT between the two dietary groups. Compared with
control mice, levels of the inflammatory cytokines MCP-1 and IL-6
were significantly elevated in VAT from ED diet-fed mice (Fig. 5C).
No significant differences were observed in concentrations of
TNF-α, IL-12, IFN-γ or IL-10 in VAT from mice fed a SD or ED
diet for 30 weeks. Assessment of leucocyte frequencies in the
stromovascular fraction demonstrated significant infiltration of
immune cells into VAT from ED diet-fed mice compared with
controls. Consistent with the significant expansion of VAT in mice
fed an ED diet, total numbers of all leucocyte subsets assessed were
increased in comparison with VAT from SD diet-fed mice.
Comparison of an equivalent mass of VAT between dietary
groups demonstrated significantly higher numbers of T cells and
macrophages (Fig. 5E) and PMN, macrophages, NK cells, B cells, T
cells, Th cells and Tc cells (Fig. 5D-H) within VAT of ED diet-fed
mice. Combined, our data are consistent with VAT inflammatory
changes described for patients with T2D, together with other
experimental models of T2D (Kohlgruber and Lynch, 2015;
Wajchenberg and Cohen, 2014).
ED diet feeding results in impaired renal function and
pathology
The impact of an ED diet on renal function was investigated through
analysis of urine (glucose and albumin:creatinine (ACR) ratio) and
Table 1. Physical, biochemical, metabolic and haematological
characteristics of mice at study end (30 weeks post-diet intervention)
Parameter (unit) SD ED P-value
Anthropometric profile
Body weight (g) 27.52 (1.59) 50.14 (4.38) <0.001*
Visceral AT (g) 0.452 (0.21) 2.731 (0.69) <0.001*
Subcutaneous AT (g) 0.418 (0.246) 3.673 (1.23) <0.001*
Liver (g) 0.969 (0.166) 1.837 (0.599) <0.001*
Spleen (g) 0.091 (0.02) 0.121 (0.025) <0.001*
Pancreas (g) 0.157 (0.029) 0.189 (0.046) 0.028*
Lung (g) 0.264 (0.061) 0.276 (0.052) 0.498
Metabolic profile
Glucose (mmol l−1) 11.5 (1.8) 15.9 (3.5) <0.001*
Insulin resistance (AUC) 1318 (188) 1887 (359) <0.001*
Insulin (ng ml−1) 0.41 (0.19) 2.15 (0.88) <0.001*
Lipid profile
Cholesterol, total (mmol l−1) 2.709 (0.417) 5.622 (1.372) <0.001*
LDL cholesterol (mmol l−1) 0.542 (0.102) 1.394 (0.558) <0.001*
HDL cholesterol (mmol l−1) 1.773 (0.294) 3.60 (0.664) <0.001*
Triglycerides (mmol l−1) 0.633 (0.1) 0.834 (0.134) 0.254
Renal profile
Microalbumin (mg l−1) 2.01 (2.00) 14.49 (11.47) <0.001*
Creatinine (mmol l−1) 4.39 (1.89) 4.65 (2.13) 0.665
ACR (mg mmol−1) 0.433 (0.412) 2.921 (2.11) <0.001*
Glucose (mmol l−1) 1.718 (0.837) 2.469 (1.43) 0.037*
Haematological profile
RBC (×1012 l−1) 9.97 (0.52) 9.70 (0.8) 0.101
WBC (×106 ml−1) 4.73 (2.20) 5.12 (1.48) 0.564
Lymphocytes (×106 ml−1) 2.70 (1.04) 2.81 (1.02) 0.755
Monocytes (×106 ml−1) 0.02 (0.02) 0.01 (0.01) 0.052
Neutrophils (×106 ml−1) 0.44 (0.30) 0.38 (0.15) 0.426
Eosinophils 0.10 (0.05) 0.12 (0.03) 0.211
Hgb (g l−1) 148.7 (1.03) 148.8 (11.9) 0.962
Hct (l l−1) 0.448 (0.02) 0.452 (0.03) 0.498
MCV (fl−1) 44.89 (0.67) 46.62 (0.96)* <0.001*
MCH (pg) 14.93 (0.25) 15.35 (0.36)* <0.001*
MCHC (g l−1) 332.5 (3.4) 329.4 (3.73)* <0.001*
Platelets (×109 l−1) 737.4 (270.5) 762.9 (296.5) 0.716
Inflammatory profile, plasma
CRP (mg l−1) 7.10 (1.08) 10.67 (1.99) <0.001*
PAI-1 (ng ml−1) 0.31 (0.09) 0.77 (0.36) <0.001*
MCP-1 (pg ml−1) 1.64 (5.72) 50.36 (52.14) <0.001*
TNF-α (pg ml−1) 0.26 (1.24) 2.50 (8.01) 0.192
Values are given asmeans, with standard deviation in parentheses. Significant
differences are analysed using an unpaired Student’s t-test with Welch’s
correction.
ACR, albumin-creatinine ratio; AT, adipose tissue; CRP, C-reactive protein;
Hct, haematocrit; HDL, high-density lipoprotein; Hgb, haemoglobin; LDL, low-
density lipoprotein; MCH, mean corpuscular haemoglobin; MCHC, mean
corpuscular haemoglobin concentration; MCP-1, monocyte chemotactic
protein 1; MCV, mean corpuscular volume; PAI-1, plasminogen activator
inhibitor type 1; RBC, red blood cells; TNF-α, tumour necrosis factor alpha;
WBC, white blood cells.
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plasma (creatinine) markers of renal impairment together with the
development of renal pathology (Fig. 7, Table 1). Compared with
mice fed a SD diet, those exposed to an ED diet demonstrated signs
of glycosuria at 30 weeks of the intervention (Table 1). Compared
with control mice, consumption of the ED diet also led to
significantly elevated plasma creatinine, a marker for progressive
renal failure in patients with T2D (Reddy et al., 2013) (Fig. 7A).
Consistent with changes in plasma markers, the ACR was
significantly higher in ED diet-fed mice at 10, 20 and 30 weeks
when compared with control animals fed a SD diet (Fig. 7B). Semi-
quantitative analysis of Jones Periodic Acid Schiff’s (PAS)-stained
glomeruli of kidneys from mice fed an SD or ED diet for 30 weeks
demonstrated glomerular damage including thickening of basement
membrane of Bowman’s capsule (asterisk) and expansion of the
mesangial matrix (arrow) (Fig. 7D,E) and hypertrophy (Fig. 7F) in
ED diet-fed mice compared with control mice. A trend for a positive
correlation between urinary ACR and mesangial thickening was
observed in mice fed an ED diet for 30 weeks (r=0.376; P=0.077).
These data suggest that consumption of an ED diet over a period of
30 weeks leads to development of kidney pathology and impaired
renal function in C57BL/6 mice, reflective of nephropathy
associated with clinical T2D.
Effect of prolonged ED diet consumption on progression
to T2D
The diagnostic criteria for clinical T2D involves a fasting plasma
glucose >7.0 mmol l−1, a two-hour post-load plasma glucose
concentration >11.1 mmol l−1 during a 75 g oral GTT and a
HbA1c >6.5% (>45 mmol mol
−1) (American Diabetes Association,
2015; D’emden et al., 2012; The Royal Australian College of
General Practitioners and Diabetes Australia, 26 Nov 2015, http://
www.racgp.org.au/your-practice/guidelines/diabetes/3-screening,-
risk-assessment,-case-finding-and-diagnosis/34-diagnosis-of-
diabetes). In congruence with this, mice in the current study were
considered T2D if they demonstrated a raised plasma glucose or
HbA1c with evidence of glucose intolerance at levels higher than the
upper 99% confidence interval for the mean of age-matched control
mice fed a SD diet. By 10 weeks, more than 90% of mice fed an ED
diet demonstrated signs consistent with T2D, with similar
proportions identified at 20 weeks post-dietary commencement
(Table S1). Glucose intolerance was evident in 100% and elevated
HbA1c levels within 95.7% of mice by 30 weeks of ED diet
consumption. After 30 weeks of consuming an ED diet, 82.6% of
mice (19 of 23) had evidence of diabetic nephropathy based on
elevated ACR and glomerular hypertrophy combined with
mesangial thickening. Our findings of metabolic, inflammatory
and pathological changes consistent with T2D suggest a feeding
regime of 10 weeks contributes to a pre-diabetic state, whilst a
regime of 30 weeks is necessary to ensure the majority of mice
progress to T2D.
DISCUSSION
The objective of this study was to evaluate whether chronic
consumption of an ED diet by C57BL/6 mice leads to the
development of key metabolic, immunologic and pathophysiological
features akin to clinical T2D. By comparing lean mice fed standard
chow with ED diet-fed mice we were able to demonstrate progressive
development of metabolic and biochemical changes and the
appearance of immunological and pathological modifications after a
30 week period. In addition to these pathognomonic signs of T2D, this
Fig. 2. Impaired glucose tolerance inmice fed an energy-dense (ED) diet.At baseline (A), 10 weeks (B) 20 weeks (C) and 30 weeks (D) after commencement
of dietary intervention, glucose concentrations were measured at 15, 30, 60 and 120 min post intraperitoneal glucose load (2 g kg−1) for control mice fed a
standard (SD; n=22) and ED (n=23) diet and the area under the curve (AUC) for glucose levels following the glucose tolerance test (GTT) determined. Data are
mean±95% c.i. Significant differences were analysed by two-way ANOVA and Sidak’s multiple comparison post-tests for GTT and Student’s t-test for AUC and
indicated as ***P≤0.001.
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model also reflects clinically relevant vascular complications
associated with T2D. These data confirm the validity of this murine
model as an accurate representation of the spectrum of
pathophysiological changes associated with the development of
clinical T2D.
While lifestyle factors and genetic predisposition provide an
indication of those most at risk of T2D, the immunopathogenesis of
this disease remains incompletely defined due to its extreme
complexity, involving alterations in multiple pathways and
processes. Consequently, various animal models of T2D have
been reported to address knowledge gaps in the aetiology,
pathophysiology, and therapeutic management of this disease.
Several rodent models of T2D are described in the literature
(Karasawa et al., 2009; King and Bowe, 2015; Sasase et al., 2015;
Scroyen et al., 2013; Shpilberg et al., 2012; Skøvso, 2014),
however, variation in the methods used to induce hyperglycaemia
thwart interpretation and comparison of findings between studies.
Notably, many of these models are based on high-fat diet feeding
regimes which do not reflect typical global dietary patterns (Harika
et al., 2013). The significant contribution of carbohydrates towards
obesity, insulin resistance and T2D has become increasingly
appreciated over the past decades (Dyson, 2015; Hu et al., 2000;
Riccardi et al., 2008; Rizkalla, 2014; Tay et al., 2015). Consumption
of ED diets, which comprise foods with a high glycaemic index, is a
risk factor for development of insulin resistance and T2D (Donin
et al., 2014; Gross et al., 2004). Comprehensive animal models that
reflect this aetiopathogenesis are lacking. Unlike other models of
diet-induced diabetes, the diet used in the current study closely
reflects the typical dietary intake of developed and developing
nations consisting of moderate levels of fat (20-35% of energy) in
combination with increased amounts of refined sugars (>10% of
energy) (Austin et al., 2011; Gross et al., 2004). The current study
confirms our previous observations that compared with those
consuming standard chow, male C57BL/6 mice fed an ED diet
begin to develop elevated fasting blood glucose and glucose
intolerance within 10 weeks of diet intervention (Hodgson et al.,
2013) with the proportion of animals exhibiting diagnostic features
of T2D increasing over the 30 week intervention period.
The enormous complexity surrounding the aetiopathogenesis of
T2D is widely appreciated and is the focus of intense research given
the emerging global impact of this chronic disease. Transition to
clinical T2D is identified through a combination of fasting plasma
glucose levels, an impaired oral GTT to determine insulin resistance
and elevated levels of HbA1c (D’emden et al., 2012). In the current
study, clinical diagnostic features of T2D were apparent in the
majority of mice after 10 weeks of consuming an ED diet with the
proportion of animals meeting the diagnostic criteria increasing over
the 30 week experimental period. Mice fed an ED diet gained
significant fat mass and displayed increased fasting blood glucose,
insulin resistance and elevated HbA1c when compared with mice
fed SD chow. At 30 weeks, HOMA-IR values revealed a
∼sevenfold increase in whole body insulin resistance for ED
diet-fed mice compared with control mice, in association with
increased pancreatic islet area and elevated pancreas insulin content
suggestive of a compensatory hyperinsulinaemic state (Bock et al.,
2003; Kahn et al., 2014).
Fig. 3. Hyperinsulinemia and pancreatic changes in energy dense (ED) diet-fed mice. (A) Fasting plasma insulin concentrations (ng ml−1) were significantly
higher in mice fed an ED (n=23) diet for 30 weeks, compared with control mice fed a standard (SD; n=22) diet. (B) Moreover, HOMA-IR values, as an indicator
of insulin resistance, were greater in ED diet-fed mice in comparison with SD control mice. (C) Pancreatic islet area was measured and expressed as a
percentage of the total pancreatic area per section for each mouse. Compared with control mice, hyperplasia of islet area was evident in pancreas from mice
fed an ED diet for 30 weeks. (D) Total insulin levels in pancreas homogenates frommice fed an ED diet for 30 weeks were elevated compared with levels in control
mice. Data are mean±95% c.i. Significant differences were analysed by Student’s t-test with Welch’s correction and indicated as ***P≤0.001.
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Consistent with the pathogenic features of clinical T2D, mice fed
an ED diet in the current study demonstrated a progressive increase
in adiposity, circulating cholesterol and triglycerides and hepatic
steatosis. Excess plasma lipids are directed to adipose tissue where
increased adiposity and impairments in adipocyte function drive the
establishment of an inflammatory environment with potential for
systemic spillover and aggravation of the insulin-resistant state
(Bays et al., 2004; Cusi, 2010; Kohlgruber and Lynch, 2015). In the
clinical setting, dyslipidaemia involving high levels of plasma LDL-
cholesterol and triglycerides, along with low levels of HDL-
cholesterol has been associated with insulin resistance and
subsequent T2D (Chehade et al., 2013). In the current study, there
was evidence of higher LDL-cholesterol, HDL-cholesterol, total
cholesterol and triglyceride in response to the ED diet at 10, 20 and
30 weeks following diet intervention. Whilst this appears to contrast
with HDL-cholesterol profiles associated with clinical T2D, it is
important to highlight that unlike humans, HDL-cholesterol is the
major apolipoprotein in mice, while LDL-cholesterol only
contributes to a small portion (Khovidhunkit et al., 2004).
Dyslipidaemia and ectopic lipid accumulation in muscle and liver
is a strong predictor of insulin resistance (Bays et al., 2004). Marked
hepatic steatosis was evident in ED diet-fed mice at 30 weeks and is
consistent with other rodent models of T2D (Hodgson et al., 2011;
Kohli et al., 2010; Lo et al., 2011).
White adipose tissue, particularly VAT, has a fundamental role
in the development of insulin resistance and T2D (Asrih and
Jornayvaz, 2013), with increased adiposity associated with
accumulation of macrophages and lymphocytes and increased
proinflammatory cytokine secretion. In the current study, in
addition to marked leucocyte infiltration, concentrations of the
proinflammatory cytokines MCP-1 and IL-6 were significantly
elevated in VAT from ED diet fed mice compared with control mice
after 30 weeks. Local impairments in insulin signalling within VAT
drives a feedforward process resulting in additional secretion of
proinflammatory cytokines with systemic spill over and worsening
insulin resistance in non-adipose tissue such as muscle and liver
(Kahn et al., 2014; Khodabandeloo et al., 2015; Revelo et al., 2014).
Similar to the clinical setting (Festa et al., 2006), plasma levels of
the acute phase proteins CRP and PAI-1 and inflammatory cytokine
MCP-1 were significantly higher in mice fed an ED diet compared
with those fed a SD diet and is consistent with systemic low grade
inflammation that is characteristic of T2D.
Many vascular complications associated with T2D arise from a
combination of hyperglycaemia, AGE formation and oxidative
stress, culminating in subclinical chronic inflammation and changes
in the proportion of immune cell subsets and function (Cucak et al.,
2014; Forbes and Cooper, 2013; Jagannathan-Bogdan et al., 2011;
Olson et al., 2015). Previous clinical investigations and
experimental studies have demonstrated a range of immune
system impairments in patients with T2D (reviewed in Hodgson
et al., 2015). Since any reduction in immune competence has to
potential to lead to increased susceptibility to infection, T2D is an
Fig. 4. Altered immune cell profile in blood of mice fed an energy-dense (ED) diet. Peripheral blood leucocyte frequencies were compared in mice fed a
standard (SD; n=16) and ED (n=15) diet for 30 weeks. (A) Compared with control mice, the percentage of B cells was significantly increased in blood fromED diet-
fedmice and corresponded with trend for decreased percentage of total T cells, though this did not reach statistical significance (P=0.056). (B) The total number of
Thelper (Th, CD4
+) cells was reduced in peripheral blood from ED diet-fed mice and was reflected by a significantly lower ratio of Th:Tcytotoxic (Tc) cells when
compared with mice fed a SD diet for 30 weeks. (C) The proportion of Tregulatory cells (Treg, CD4
+CD25+) was significantly lower in blood from mice fed an ED diet
for 30 weeks, despite comparable absolute numbers of Treg cells between dietary groups (P=0.28). (D) Similarly, the percentage of peripheral blood natural killer T
(NKT) cells was significantly reduced for ED diet-fed mice with a trend for an overall reduction in the total number of NKT cells (P=0.1). Data are mean±95% c.i.
Significant differences were analysed by Student’s t-test with Welch’s correction and indicated as *P≤0.05, **P≤0.01.
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important risk factor for many infectious diseases, including
tuberculosis (Bridson et al., 2014; Martinez and Kornfeld, 2014).
There is growing interest in utilising clinically relevant animal
models of T2D to investigate mechanisms of immune dysfunction
that underlie susceptibility of individuals with T2D to co-morbid
infectious diseases caused by pathogens such as Mycobacterium
Fig. 5. Visceral adipose tissue pathology in energy dense (ED) diet-fed mice. (A) Representative photomicrographs of visceral adipose tissue (VAT) from
standard (SD; n=22) and ED (n=23) diet-fed mice after 30 weeks. (B) Mean adipocyte size (μm2) was significantly greater in VAT from mice fed an ED diet,
compared with those fed a SD diet. (C) Concentrations (pg ml−1) of the inflammatory cytokines monocyte chemotactic protein 1 (MCP-1) and interleukin (IL)-6
were markedly higher in VAT of mice fed an ED diet for 30 weeks, compared with SD diet-fed mice. Consistent with this, comparison of equivalent masses
(100 mg) of VAT from SD (n=16) and an ED (n=15) diet-fed mice demonstrated significant differences in the frequencies of (D) PMN, (E) macrophages, (F) NK
cells, (G) B and T cells and (H) Thelper (Th) and Tcytotoxic (Tc) cells within the stromal vascular fraction. Data are mean±95% c.i. Significant differences were
analysed by Student’s t-test with Welch’s correction and indicated as **P≤0.01, ***P≤0.001, ****P≤0.0001.
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tuberculosis and Burkholderia pseudomallei (Bridson et al., 2014;
Hodgson et al., 2015; Martinez and Kornfeld, 2014). In the current
study, whilst the total leucocyte frequency in peripheral blood was
comparable between the two dietary groups, the proportion of Th,
Treg, and NKT cells was significantly lower for ED diet-fed mice
than control mice which is consistent with clinical findings (Cucak
et al., 2014; Jagannathan-Bogdan et al., 2011; Magalhaes et al.,
2015; Olson et al., 2015; Pedicino et al., 2013). Given the
importance of these cells in orchestrating protective cell-mediated
immune responses that are crucial for clearance of intracellular
pathogens (Hodgson et al., 2015), future investigations into the
significance of this altered T cell profile in mounting subsequent
effective innate and adaptive immune responses to infectious
onslaughts are warranted.
Patients with T2D have an increased incidence of
microangiopathies, particularly retinopathy, neuropathy and
nephropathy, and are at an increased risk of cardiovascular
and atherogenic diseases including atherosclerosis, myocardial
infarction and cerebral ischaemic events (Fowler, 2008). The
foremost complication associated with T2D is chronic renal failure
which is commonly screened for in the clinical setting by measuring
urine and plasma protein levels, namely microalbumin, creatinine
and albumin-creatinine ratio (ACR) (American Diabetes
Association, 2004; Chadban et al., 2010). The presence of
microalbuminuria is highly predictive for development of end
stage kidney failure and can also provide an indication of those
patients most at risk of developing other vascular complications
(Chadban et al., 2010). In the current study, animals fed an ED diet
for 30 weeks had elevated microalbuminuria and plasma creatinine
when compared with control mice fed a SD diet. Moreover, renal
impairment in ED diet-fed mice was confirmed histologically with
evidence of glomerular hypertrophy and glomerular basement
membrane and mesangial matrix thickening, each of which are
hallmark features of diabetic nephropathy (Danda et al., 2005; Jha
et al., 2015; Matsubara et al., 2006). Our findings highlight the
utility of this T2D model for future investigations to identify early
markers of diabetic nephropathy and to assess new therapeutic
targets for managing this condition.
Fig. 6. Hepatic steatosis in mice
fed an energy-dense (ED) diet.
(A-D) Photomicrographs of representative
liver sections from mice fed a standard (SD;
n=22) or ED (n=23) diet for 30 weeks that
were stained with (A,C) H&E or (B,D) Oil
Red O. 400× magnification (E) The
percentage of Oil Red O staining within
sections was compared using digital analysis
software and demonstrates marked hepatic
steatosis in ED diet-fed mice, compared with
control mice. Data are mean±95% c.i.
Significant differences were analysed by
Student’s t-test with Welch’s correction and
indicated as ***P≤0.001.
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While there were significant elevations in metabolic parameters
after 10 weeks of ED diet feeding in the current study,
complications of T2D require time to develop through chronic
exposure to hyperglycaemia and AGE accumulation. Therefore, a
30-week feeding regime was used to not only establish metabolic
dysfunction in a greater proportion of animals, but to also reflect the
chronic progression of vascular complications associated with T2D.
It is important to acknowledge that just as the T2D population is not
a homogenous group, there was broad variation in body weight gain
and metabolic changes in mice consuming an ED diet in the current
study. Notably, some animals consuming the ED diet failed to
develop hyperglycaemia and/or elevated HbA1c within the 30-week
experimental period. Our data highlights the importance of a
standardised animal model of T2D with comprehensive baseline
characterisation of both metabolic, biochemical and inflammatory
parameters and screening of individual mice for studies utilising
diet-induced models of T2D to ensure only those meeting the
clinical diagnostic criteria of T2D are included for subsequent
investigations. The polygenic murine model of T2D described in the
current study offers several advantages to conventional T2D
models: (1) use of a diet containing moderate levels of fat
combined with high glycaemic index more closely reflects global
dietary patterns than other models based on HFD-feeding; (2) unlike
other models of T2D which use short-term diet interventions, the
model described in the current study is based on chronic diet
intervention and therefore not only more closely reflects the many
years that it takes for progression from pre-diabetes to overt T2D
and its vascular complications in humans, but also more closely
simulates the mean age of diagnosis of T2D (>45 years; Age at
Diagnosis, Centers for Disease Control and Prevention, 26 Nov
2015, http://www.cdc.gov/diabetes/statistics/age/fig1.htm); and
(3) in contrast to previous studies describing a selective snapshot
Fig. 7. Nephropathy in energy-dense (ED) diet-fed mice. (A,B) Changes in (A) plasma creatinine levels and (B) urinary albumin:creatinine ratio (ACR) over
30 weeks of feeding reflect progressive impairment in renal function in mice fed an ED diet. (C,D) Representative Jones Periodic Acid Schiff’s (PAS)-stained
paraffin sections of kidney frommice fed a (C) standard (SD; n=22) or (D) ED (n=23) diet for 30 weeks are shown. Scale bar: 50 μm. Pronounced nephropathy was
observed in kidneys from mice fed an ED diet including thickening of Bowman’s capsule (arrow) and mesangial thickening (asterisk). (E) Comparison of
PAS-positive staining demonstrated significant mesangial thickening within glomeruli of kidneys from ED diet-fed mice, compared with control SD-fed mice.
(F) Glomerular hypertrophy was also evident in kidneys frommice fed an ED diet for 30 weeks. Data are mean±95% c.i. Significant differences were analysed by
two-way ANOVA and Sidak’s multiple comparison post-tests for plasma creatinine and ACR and Student’s t-test with Welch’s correction for PAS-staining.
*P≤0.05, **P≤0.01, ***P≤0.001.
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of a particular feature of T2D, the current study provides a
comprehensive, longitudinal characterisation of changes in
metabolic, biochemical, inflammatory, immunological and
pathological markers within individual mice, thereby
demonstrating the progressive development of diagnostic features
of T2D.
In conclusion, data from the current study demonstrates that
consumption of an ED diet consisting of moderate levels of fat
and a high glycaemic index leads to the development of obesity,
hyperglycaemia, insulin resistance, hyperlipidemia, chronic
inflammation and impaired renal function in male C57BL/6 mice
over a period of 30 weeks. This model closely simulates the
progression to overt T2D, incorporating metabolic dysregulation
and systemic inflammation and will provide an important tool for
elucidating the molecular and cellular mechanisms involved in
progression from pre-diabetes to overt T2D. In addition to its
applications for studies into the pathophysiology of T2D and
evaluation of glucose-lowering therapies, this model will be highly
valuable for improving our understanding of the mechanisms
contributing to the vascular complications associated with T2D.
Given the continued global convergence of communicable and non-
communicable diseases, the availability of a clinically relevant, non-
genetic animal model of T2D such as that described in the current
study, will also be pivotal in elucidating the immunological basis of
the synergy between T2D and infections such as tuberculosis.
MATERIALS AND METHODS
Animals and diets
Male C57BL/6J mice were obtained from the Animal Resource Centre
(Perth, WA, Australia) and housed in cages within a temperature and light
controlled environment (22°C, 12 h day/night cycle). Ear tagging was used
to enable longitudinal characterisation of individual mice across the study
period. After two weeks of being housed with a regular diet, mice (five
weeks of age) were divided randomly into two dietary groups. One group
received ad libitum access to an ED diet [ED, n=23; Specialty Feeds, Glen
Forrest, WA, Australia: SF03-030, 23% fat, 19% protein, 50.5% refined
carbohydrates (dextrose), 7.5% fibre]. Control mice received isometric
quantities of standard rodent diet (SD, n=22; Goldmix Stockfeeds, South
Lismore, NSW, Australia: Rat and Mouse Nuts: 4.8% fat, 20% protein,
62.8% complex carbohydrates, 12.4% fibre). To control for possible
differences in consumption rates due to palatability of the diets, control mice
received an isometric quantity of food based on the daily consumption of
paired ED diet-fed mice calculated during the previous week.
Two series of experiments were conducted in parallel. In the first series,
longitudinal studies were conducted on mice fed an SD (n=22) or an ED
(n=23) diet for 30 weeks. Changes in metabolic and biochemical parameters
were assessed in vivo at baseline and at indicated time points throughout the
30 week intervention. At 30 weeks, these mice were euthanised and organs
processed for histological analysis. In the second experimental series, mice
were fed an SD (n=16) or an ED (n=15) diet for 30 weeks. Following
confirmation of T2D status (glucose intolerance, elevated fasting blood
glucose and altered plasma and urine biochemical profile), the second series
of mice were euthanised, cardiac blood collected for haematological
analysis and tissues processed for measurement of inflammatory cytokines
and leucocyte phenotyping. Experiments were carried out in accordance
with National Health and Medical Research Council guidelines and were
approved by the institutional ethics committee (A2016).
Anthropometric measurements and sample collection
The average daily food intake per mouse was calculated weekly over the
30-week dietary intervention. Body weight of mice was monitored weekly
throughout the study period. At 0, 10, 20 and 30 weeks following
commencement of the intervention, whole blood was collected via retro-
orbital bleed from 6 h-fasted mice, with 50 μl stored for HbA1c analysis and
the remainder centrifuged for collection of plasma (15,000 g, 10 min, room
temperature). Samples were stored at −80°C until further biochemical
analysis. Urine was collected from mice at baseline, 10, 20 and 30 weeks
post-diet intervention and stored at −80°C until further analysis. An
intraperitoneal GTT was performed on 6 h fasted mice at 0, 10, 20 and
30 weeks post commencement of the intervention.
Following completion of in vivo analyses at 30 weeks post-diet
commencement, mice were euthanised by CO2 asphyxiation for end point
analyses. Whole blood and plasma was collected after cardiac puncture for
measurement of biochemical parameters. Liver, lung, spleen, VAT and SAT
were excised, weighed and processed for histology.
Fasting blood glucose, insulin and glucose tolerance test
Fasting blood glucose (FBG) was assessed and an intraperitoneal GTT
performed on mice at baseline and at 10, 20 and 30 weeks post-dietary
intervention following a 6 h fast. Blood glucose levels were measured in tail
vein blood using an Accu-Chek® Performa point of care blood glucose
meter (Roche, Castle Hill, NSW, Australia) prior to and at 15, 30, 60
and 120 min post-injection of glucose (2 g kg−1 lean body mass).
Hyperglycaemic threshold, as a marker for T2D, was set at 3 standard
deviations above the mean (>11.0 mmol l−1) for control male C57BL/6
mice as described previously (Hodgson et al., 2013). The trapezoidal rule
was used to determine AUC for the GTT (Hodgson et al., 2013).
At 30 weeks post-dietary intervention, plasma was separated from tail
vein blood collected during the GTT and used for measurement of changes
in total insulin of mice following glucose challenge. Fasting insulin levels
were also measured in plasma from terminal bleed of mice at study end
(30 weeks) using a commercially available Mouse Ultrasensitive ELISA kit
(ALPCO, Salem, NH, USA) was used to measure total insulin in samples as
per the manufacturer’s instructions.
The homeostasis model assessment (HOMA) is widely used to estimate
insulin resistance (HOMA-IR) (Wallace et al., 2004). HOMA-IR was
calculated based on the following formulae: fasting glucose
(mmol l−1)×fasting insulin (μU ml−1)/99.95. Typically, a constant of 22.5
is used for calculating HOMA-IR which is based on normal reference ranges
of fasting glucose and insulin. To account for physiological differences
between humans and rodents, an adjusted constant of 99.95 was used in the
HOMA-IR calculation and was determined from multiplying the median
levels of fasting blood glucose (11.8) and fasting insulin (8.47) from n=22
normal male C57BL/6 mice.
Biochemical analyses
All biochemical analyses were performed using an AU480 Chemistry
Analyser (Beckman Coulter, Mt Waverly, VIC, Australia) according to
manufacturers’ instructions. Total (Hb) and HbA1c were measured in
whole blood. Circulating glucose, triglyceride and cholesterol (total,
HDL- and LDL-cholesterol), creatinine, albumin and CRP were measured
in plasma. Glucose, microalbumin and creatinine concentrations were
measured in urine. Total PAI-1, a marker of subclinical chronic
inflammation whose expression is predictive of insulin resistance and
development of T2D (Festa et al., 2006), was measured in plasma using a
commercially available ELISA kit (Abcam, Melbourne, VIC, Australia)
according to the manufacturer’s instructions.
Pancreatic insulin content
At study end, pancreas were excised, weighed then homogenised in 1 ml of
ice-cold acid-ethanol. Homogenates were stored overnight at 4°C then
centrifuged (500 g, 30 min, 4°C) and the supernatant fractions transferred
to fresh tubes. Samples were neutralised by addition of an equal volume of
1 M Tris pH 7.5. Insulin concentration was determined in pancreatic
supernatants using a commercially available ELISA (ALPCO) and insulin
content expressed as μg insulin per pancreas.
Histology
Liver, kidney, pancreas and adipose tissue (subcutaneous and visceral) were
fixed in 10% formalin for 48 h. Liver was cryosectioned (4 μm thickness) in
O.C.T. medium (Tissue Tek, Olympus, Notting Hill, VIC, Australia) and
stained with Oil Red O (Sigma Aldrich, Castle Hill, NSW, Australia) to
evaluate neutral lipid accumulation. Kidney, pancreas and adipose tissue
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was embedded in paraffin and sectioned at 4 μm thickness. Sections were
stained with haematoxylin and eosin (H&E, ProSciTech, Kirwan, QLD,
Australia) or PAS (ProSciTech) for morphology evaluation. All stained
section were visualised on a computer connected to a light microscope
(BX43 Olympus). Quantitative analysis of tissues was performed on digital
images (20× magnification) using cellSens™ image analysis software
(Olympus). Histological analyses for each tissue were conducted on a
representative section from mice that had been fed a SD (n=22) or ED
(n=23) diet for 30 weeks. Threshold-based phase segmentation was used to
compare the extent of neutral lipid accumulation in liver sections from each
mouse. The mean size of adipocytes within VAT from each mouse was
determined by measuring the area of a minimum of 50 adjacent adipocytes
per section. The total pancreatic area was determined from H&E stained
sections from individual mice. The total number of islets of Langerhan’s per
section was counted and the area of each islet measured. Data was expressed
as the percentage islet area within the total pancreatic area for each mouse. In
the kidney, threshold-based segmentation was applied to PAS-stained
sections to compare PAS-positive staining within the glomerular capillary
tuft, relative to the total glomerular area. The circumference of each
glomerulus was outlined using the polygonal tracing tool and the glomerular
area computed. A minimum of 30 glomeruli per kidney were assessed.
Glomeruli were selected that were sectioned through the canter of the tuft
and were free of artefacts. Selection bias was minimised by beginning at
equivalent points in the outer cortex, moving clockwise and selecting the
first acceptable glomerulus. Remaining glomeruli were selected by
continuing around the cortex and selecting approximately equal numbers
of glomeruli from the outer and middle zones of the cortex.
Inflammatory cytokines
Plasma and visceral adipose tissue cytokine levels were determined by
cytometric bead array [CBA; Mouse Inflammation Kit, (IL-6, IL-12p70,
IL-10, TNF-α, IFN-γ and MCP-1); BD Biosciences, North Ryde, NSW,
Australia]. Samples were analysed in duplicate according to the
manufacturer’s instructions. Data was acquired on a FACSCalibur flow
cytometer using CellQuest Pro (BD Biosciences).
Leucocyte phenotyping
Following confirmation of T2D status (elevated FBG and HbA1c, impaired
glucose tolerance), a second series of mice fed an SD (n=16) or an ED
(n=16) diet for 30 weeks were euthanised and tissues processed for
leucocyte phenotyping in peripheral blood and VAT. Heparinised whole
blood was also used for haematological analysis. Haematological analysis
was performed on heparinised whole blood using a COULTER®Ac-T diff
Analyser (Beckman Coulter). Using the Veterinary Applications software,
the following parameters were determined: RBC and WBC count, platelet
count, haematocrit (Hct), Hgb, MCH, MCHC, and MCV.
Visceral adipose tissue was excised, weighed then cut into small pieces
and digested with collagenase type II (Sigma Aldrich) in Hanks Balanced
Salt Solution (HBSS) with periodic mechanical disruption. The cell
suspension was then filtered through 1 μm mesh and the stromovascular
fraction collected after centrifugation (400 g, 8 min, room temperature) and
washing in HBSS containing 2.5 mM EDTA.
Cells from peripheral blood and the stromovascular fraction were pre-
incubated with an anti-FcgRII/III monoclonal antibody (mAb, clone 93,
eBioscience, San Diego, CA, USA) for 15 min then with appropriate mAbs.
The followingmAbswere used (1 in 125 dilution): fluorescein isothiocyanate
(FITC)-conjugated anti-TCRβ (clone H57-597) and anti-CD3e (clone 145-
2C11); Alexa Fluor (AF) 488-conjugated anti-Ly6G (clone RB6-8C5);
phycoerythrin (PE)-conjugated anti-CD4 (clone RM4-5), anti-NKp46 (clone
29A1.4) and anti-MHC Class II (clone M5/114.15.2); peridinin chlorophyll
(PerCP)-conjugated anti-CD45 (clone 30-F11); PerCP-Cy5.5-conjugated
anti-B220 (cloneRA3-6B2), anti-CD25 (clone PC61) and anti-CD11c (clone
N418); allophycocyanin (APC)-conjugated anti-CD8 (clone 53-6.7); AF
647-conjugated anti-CD3 (clone 17-A2) and anti-CD11b (clone);
biotinylated anti-F4/80 (clone BM8) detected with streptavidin-conjugated
PE (all from eBioscience and BD Biosciences). For assessment of NKT cell
frequency in peripheral blood, CD1d Dimer X was purchased from BD
Biosciences and alpha galactosylceramide (α-GalCer) was purchased from
Adipogen (Epalinges, Switzerland). CD1d/α-GalCer dimer was prepared
according to the manufacturer’s protocol and detected using PE-conjugated
anti-mouse IgG1 (clone A85-1; BD Biosciences). Samples containing PE-
labelled α-GalCer-unloaded CD1d-Ig dimer were included as controls.
Following cell surface staining, erythrocytes were lysed with RBC lysis
buffer (eBioscience), cells fixed with 1% paraformaldehyde for 10 min then
washed twice before resuspension in phosphate buffered saline (PBS,
pH 7.4). Data was acquired on a FACSCalibur flow cytometer using
CellQuest Pro (BD Biosciences). 123count eBeads (eBioscience) were
added to samples immediately prior to acquisition to enable enumeration of
leucocyte subsets. A minimum of 105 blood leucocytes and 104 leucocytes
from VAT were acquired. Leucocytes were phenotyped according to the
following parameters: leucocytes (CD45+), PMN (SSChiLy6G+), B cells
(CD3−B220+), T cells (CD3+B220−), Th cells (CD3
+CD4+), Tc cells
(CD3+CD8+), Treg cells (CD3
+CD4+CD25+), NKT cells (TCRβ+CD1d/α-
GalCer dimer+), NK cells (CD3-NKp46+), professional phagocytic cells
(CD11b+MHC II+) and tissue macrophages (F4/80+). The percentage of
each leucocyte subset in peripheral blood from mice fed an SD or ED diet
was compared, together with the absolute number of leucocytes per ml of
blood. To account for the significant difference in VAT mass from SD and
ED diet-fed mice, leucocyte frequencies were compared in an equivalent
volume of VAT (100 mg).
Statistical analysis
Statistical analyses were conducted using GraphPad Prism 6.0 software.
Biochemical, metabolic and immunological parameters were compared
between SD and ED diet-fed mice at each time point using a Student’s
t-test with Welch’s correction. Data arising from repeatedly measured
variables were subjected to two-way ANOVAwith Tukey post-hoc test for
select comparison. Correlation between glycaemic parameters (blood
glucose, GTT-AUC, HbA1c) and other measurements were also assessed
via the Spearman correlation and linear regression analysis. Data are
expressed as mean±95% confidence intervals (c.i.). Significance was set at
P≤0.05.
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